Thalidomide administration inhibits the clinical evolution of the experimental autoimmune encephalomyelitis (eae) in lewis rats: preliminar results
Rev. interdisciplin. estud. exp. anim. hum. (impr.)
; 1(2): 58-61, Junho 2009. tab
Article
in En
| LILACS
| ID: biblio-964323
Responsible library:
BR1.1
ABSTRACT
Multiple sclerosis (MS) is a chronic neurodegenerative inflammatory disease of the central nervous system. Several immunomodulatory agents have been used to prevent MS acute exacerbations. Tumor Necrosis factor alpha (TNFα) and interferon gamma (IFN-γ) are two major inflammatory mediators. Recently, we investigated in our laboratory the therapeutic value of thalidomide, a recognized TNF-α inhibitor, for the treatment of MS using the classical Lewis rat model of experimental autoimmune encephalomyelitis ( EAE). The experimental study revealed that thalidomide reduces the incidence of EAE development in 90% of the cases. Hence we hypothesized that thalidomide may be an important therapeutical tool for prevention of acute exacerbations of the MS.
Key words
Full text:
1
Index:
LILACS
Main subject:
Thalidomide
/
Multiple Sclerosis, Relapsing-Remitting
/
Encephalomyelitis, Autoimmune, Experimental
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Rev. interdisciplin. estud. exp. anim. hum. (impr.)
Journal subject:
BIOLOGIA
Year:
2009
Type:
Article